Related Experiment Videos
Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy
Insights
Pediatric myasthenia gravis (MG) showed minimal response to cholinesterase inhibitors. Prednisone and thymectomy led to remission in both children, avoiding long-term steroid complications.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
- Pediatric MG presents unique diagnostic and therapeutic challenges.
- Cholinesterase inhibitors offer limited efficacy in some pediatric MG cases.
Observation:
- Two children diagnosed with myasthenia gravis at ages 2 and 3 experienced minimal improvement with cholinesterase inhibitors.
- One patient presented with ocular symptoms, while the other had generalized MG.
- Muscle biopsy in one patient revealed lymphorrhages, suggesting an inflammatory process.
Findings:
- A 3-month course of prednisone followed by thymectomy induced remission in both patients.
- Remission was sustained for 12 and 8 months post-thymectomy.
- Residual ocular weakness showed improved responsiveness to anticholinesterase drugs after thymectomy.
Implications:
- Combined prednisone and thymectomy offers an effective treatment strategy for pediatric myasthenia gravis.
- This approach avoids the long-term adverse effects of chronic steroid use, such as growth retardation.
- Thymectomy may improve the efficacy of anticholinesterase inhibitors in managing residual symptoms.
Abstract:
Myasthenia gravis developed in two children at 2 and 3 years of age respectively. Minimal improvement followed chronic oral administration of cholinesterase inhibitors. Patient 1 had ptosis and ophthalmoplegia but no clinical or electromyographic involvement of muscles of the extremities, although a quadriceps muscle biopsy revealed lymphorrhages. Patient 2 had progressive generalized myasthenia for 3 1/2 years. Both children were given a 3-month course of prednisone followed by thymectomy. They both are in remission, 12 and 8 months after thymectomy, with only minimal residual ocular weakness, but this weakness is much more responsive to anticholinesterase drugs than before thymectomy. Long-term administration of steroids, with the attendant complication of growth retardation, is avoided.